Company not in compliance with the continued listing standards of NYSE American LLC ("NYSE American" or the "Exchange") and that its listing is being continued pursuant to an extension granted by NYSE Regulation. The targeted completion date of the plan period (the "New Cure Deadline") is April 15, 2027.

As previously disclosed, the Company is not in compliance with Sections 134 and 1101 of the NYSE American Company Guide (the "Company Guide") because it failed to timely file with the U.S. Securities and Exchange Commission (the "SEC") its Annual Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 (collectively, the "Delayed Filings").

Pursuant to Section 1007 of the Company Guide, a company that is unable to cure a filing delinquency within the initial six-month period of the maximum 12-month cure period is required to submit an extension request. On October 1, 2026, the Company submitted an extension request to NYSE Regulation. On October 7, 2026, the Company received a letter from NYSE Regulation informing the Company that NYSE Regulation had reviewed and accepted the extension request and granted the Company a plan period through April 15, 2027 to complete the Delayed Filings and any subsequently delayed filings with the SEC.

NYSE Regulation staff will review the Company periodically for compliance with adherence to the milestones in the plan. If the Company does not make progress consistent with the plan during the plan period, or if the Company does not complete the Delayed Filings and any subsequently delayed filings with the SEC by the end of the maximum 12-month cure period on April 15, 2027, Exchange staff will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.

The Company's common stock will continue to be listed and traded on NYSE American during the plan period, subject to the Company's compliance with the plan and other applicable continued listing requirements, and will continue to bear a late filer (".LF") indicator until the filing delinquency is cured. The extension does not have any immediate effect on the listing or trading of the Company's common stock.

The Company is working diligently to complete the Delayed Filings and currently expects to file them on or before the New Cure Deadline; however, there can be no assurance that the Company will do so or that it will regain compliance with the NYSE American continued listing standards.